Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
By India Edwards HealthDay Reporter
WEDNESDAY, Feb. 5, 2025 -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.
A new study found that a drug in the same class called exenatide, marketed as Byetta, had no effect on slowing the disease or easing its symtoms.
The trial, published Feb. 4 in The Lancet, followed 194 people with Parkinson's disease for 96 weeks.
Patients were randomly assigned to inject either Byetta or a placebo once a week. The results? Disappointing.
"We found no evidence to support exenatide as a disease-modifying treatment for people with Parkinson's disease," researchers wrote.
There was no improvement in symptoms; no slowing of brain degeneration; no benefit on brain scans; no positive effect.
“It’s hugely disappointing,” Dr. Thomas Foltynie of University College London, who led the trial, told The New York Times. “We were expecting we would come through and we would get a positive result.”
For years now, researchers have hoped that GLP-1 drugs, which have revolutionized treatment of diabetes and weight loss, could also protect neurons and slow brain disease.
In fact, early animal lab studies and smaller clinical trials suggested potential benefits, The Times reported.
But this larger study offered no clear evidence that GLP-1 drugs work for Parkinson's.
“This is a sobering moment,” Dr. Michael S. Okun, a Parkinson’s disease expert at the University of Florida and national medical adviser for the Parkinson’s Foundation, told The Times. “This is a really well done study and it came up empty-handed.”
The study could also impact research into GLP-1 drugs for Alzheimer’s disease, as some researchers have been testing whether these medications might help slow cognitive decline.
But Parkinson’s specialists warn that without a clear understanding of how GLP-1 drugs work in the brain, future studies may be just as disappointing.
“I wouldn’t do another study like this unless you learn what is the target,” Dr. David Standaert, a Parkinson’s researcher at the University of Alabama at Birmingham, told The Times. “What is the biochemistry you are trying to change in the brain? How do these drugs work, anyway?”
Sources
- The New York Times, media report, Feb. 4, 2025
- The Lancet, Feb. 4, 2025
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Microbiome Linked To Memory Issues, Dementia In Parkinson's Patients
FRIDAY, June 13, 2025 — A person’s microbiome – the bacteria naturally living in the mouth and gut – might contribute to Parkinson’s disease, a new...
Ultra-Processed Foods Linked To Parkinson's Disease Risk
THURSDAY, May 8, 2025 -- Fast food and ready-made packaged eats could be doing slow damage to people’s brains. Ultra-processed foods like breakfast cereals, soft drinks...
Common Meds Appear To Delay Onset Of Parkinson's Disease
THURSDAY, April 17, 2025 -- Common medications like aspirin, ibuprofen, statins and beta blockers appear to slow the progress of Parkinson’s disease, a new study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.